Gustavo Baldassarre
Overview
Explore the profile of Gustavo Baldassarre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
2632
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pasto B, Buzzatti G, Schettino C, Malapelle U, Bergamini A, De Angelis C, et al.
Crit Rev Oncol Hematol
. 2024 May;
199:104379.
PMID: 38718940
The emerging era of precision medicine is characterized by an increasing availability of targeted anticancer therapies and by the parallel development of techniques to obtain more refined molecular data, whose...
12.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Apr;
16(5):1162-1192.
PMID: 38658801
Platinum (PT)-resistant Epithelial Ovarian Cancer (EOC) grows as a metastatic disease, disseminating in the abdomen and pelvis. Very few options are available for PT-resistant EOC patients, and little is known...
13.
Rampioni Vinciguerra G, Capece M, Reggiani Bonetti L, Nigita G, Calore F, Rentsch S, et al.
Signal Transduct Target Ther
. 2024 Feb;
9(1):31.
PMID: 38342897
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, characterized by an intense desmoplastic reaction that compresses blood vessels and limits nutrient supplies. PDAC aggressiveness largely relies on its extraordinary capability...
14.
Favero A, Segatto I, Capuano A, Mattevi M, Rampioni Vinciguerra G, Musco L, et al.
NPJ Breast Cancer
. 2024 Jan;
10(1):5.
PMID: 38184660
The extracellular matrix (ECM) is an important component of the tumor microenvironment and undergoes extensive remodeling during both initiation and progression of breast cancer (BC). EMILIN1 is an ECM glycoprotein,...
15.
Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al.
Nat Commun
. 2023 Nov;
14(1):7129.
PMID: 37932286
No abstract available.
16.
Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al.
Nat Commun
. 2023 Oct;
14(1):6777.
PMID: 37880212
Reprogramming of amino acid metabolism, sustained by oncogenic signaling, is crucial for cancer cell survival under nutrient limitation. Here we discovered that missense mutant p53 oncoproteins stimulate de novo serine/glycine...
17.
Coan M, Toso M, Cesaratto L, Rigo I, Borgna S, Pieta A, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762037
is the most frequently mutated gene in human cancers. Most genomic alterations are missense mutations, which cause a loss of its tumour suppressor functions while providing mutant p53 (mut_p53) with...
18.
Fejza A, Camicia L, Carobolante G, Poletto E, Paulitti A, Schinello G, et al.
Matrix Biol
. 2023 Aug;
122:18-32.
PMID: 37579864
Angiogenesis, the formation of the new blood vessels from pre-existing vasculature, is an essential process occurring under both normal and pathological conditions, such as inflammation and cancer. This complex process...
19.
Segatto I, Rampioni Vinciguerra G, Pellarin I, DallAcqua A, Berton S, Citron F, et al.
Cancer Commun (Lond)
. 2023 Jun;
43(7):844-849.
PMID: 37337406
No abstract available.
20.
Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto A, et al.
Oncogene
. 2022 Dec;
42(5):406.
PMID: 36544045
No abstract available.